{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"6.4","value":"3.0"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"9.5","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Non-Hodgkin Lymphoma (NHL): Diffuse Large B-cell Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: Follicular Lymphoma Grade 3B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"3.9","value":"2.2"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"12.6","value":"4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NIH: High-Grade B-cell Lymphoma with DLBCL Histology"},{"categories":[{"measurements":[{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"1.0","upperLimit":"NA","value":"2.2"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"NIH: Primary Mediastinal (thymic) Large B-cell Lymphoma"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.3","upperLimit":"NA","value":"NA"},{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: T Cell/Histiocyte-Rich Large B-Cell Lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"7.5","value":"4.4"},{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"9.4","upperLimit":"NA","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Diffuse Large B-cell Lymphoma (DLBCL): DLBCL NOS de novo"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"11.2","value":"2.1"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.9","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"DLBCL: DLBCL from Transformed Indolent NHL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"4.9","value":"2.1"},{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"6.0","upperLimit":"NA","value":"11.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"DLBCL: Germinal Center B-cell like (GCB)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"7.5","value":"2.3"},{"comment":"The upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"4.9","upperLimit":"NA","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"DLBCL: Activated B-cell-like, non-GCB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"3.9","value":"2.1"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"12.6","value":"4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NHL: Double-hit lymphoma (DBL)/triple-hit lymphoma (THL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"6.4","value":"2.8"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"15.6","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"NHL: Non-DHL/THL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Time from randomization to death, progressive disease (PD), failure to achieve complete response (CR) or partial response (PR) by 9 weeks or start of new antineoplastic therapy, whichever occurs first. CR: Target nodes masses must regress to ≤ 1.5cm in LDi, no extralymphatic sites, no new lesions. PR: ≥ 50% decrease in sum of diameters of up to 6 target nodes and extranodal sites, no new lesions, spleen must have regressed \\> 50% in length. PD: LDi \\> 1.5cm, increase by ≥ 50% from PPD nadir, an increase in LDi or SDi from nadir, 0.5 cm for lesions ≤ 2cm, 1.0cm for lesions \\> 2cm. Complete metabolic response: Lymph nodes score 1, 2, 3 with/without residual mass on 5-point scale, no new lesions, no FDG-avid disease. Partial metabolic response: Lymph nodes score 4 or 5, reduced uptake from baseline, no new lesions, residual uptake higher than normal, reduced from baseline. Progressive metabolic disease: Score 4 or 5 with an increase in uptake intensity from baseline and/or new FDG-avid.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized participants per clinical, histological and molecular subgroups that are pre-specified for EFS (subgroups are not mutually exclusive)","reportingStatus":"POSTED","timeFrame":"From randomization to death from any cause, PD, failure to achieve CR or PR by 9 weeks post randomization, or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first (Up to 36 months)","title":"Event-free Survival (EFS) by Subgroups","type":"SECONDARY","unitOfMeasure":"Months"}